ERVFRD-1 and hematopoietic and lymphoid cell neoplasm: Also in hematological cancer cell lines, HERVs up-regulation (FC ≥2) was observed with a higher frequency in guadecitabine- or DAC- vs. AZA-treated cells being 10% and 10% vs. 10% (Syncytin-1), 20% and 20% vs. 10% (Syncytin-2), 60% and 60% vs. 30% (ENV-T), 60% and 60% vs. 20% (ERV9-1), 50% and 60% vs. 20% (ENV-MER34), 10% and 10% vs. 0% (ENV-FXA34), 40% and 40% vs. 20% (ENV-Fb1) and 80% and 80% vs. 30% (ENV-Fc2).